(Q54497269)

30 May 2018

title

Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. (English)

1 reference

30 May 2018

1 reference

3

1 reference

30 May 2018

Yasushi Yatabe

2

object named as

Yasushi Yatabe

1 reference

30 May 2018

author name string

Kohei Shitara

1

1 reference

30 May 2018

Masato Sugano

4

1 reference

30 May 2018

Chihiro Kondo

5

1 reference

30 May 2018

Daisuke Takahari

6

1 reference

30 May 2018

Takashi Ura

7

1 reference

30 May 2018

Masahiro Tajika

8

1 reference

30 May 2018

Seiji Ito

9

1 reference

30 May 2018

Kei Muro

10

1 reference

30 May 2018

publication date

14 July 2012

1 reference

30 May 2018

published in

Gastric Cancer

1 reference

30 May 2018

volume

16

1 reference

30 May 2018

issue

2

1 reference

30 May 2018

page(s)

261-267

1 reference

30 May 2018

https://scigraph.springernature.com/pub.10.1007/s10120-012-0179-9

exact match

0 references

cites work

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-012-0179-9

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

21 January 2018

1 reference

12 December 2020

Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays

1 reference

12 December 2020

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

12 December 2020

Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer

1 reference

12 December 2020

10.1007/S10120-012-0179-9

Identifiers

DOI

1 reference

30 May 2018

1 reference

30 May 2018